Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $358.37M.
ENTERPRISE VALUE (EV)
$358.37M
Galectin Therapeutics Inc.
Market Cap
$242.35M
Enterprise Value (EV)
$358.37M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $242.35M | $358.37M |
| InflaRx N.V. (IFRX)vs › | $241.56M | $75.17M |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.98M | $139.39M |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.97M | $156.22M |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $246.67M | $237.79M |
| High Tide Inc. (HITI)vs › | $237.69M | $292.15M |
| BioAge Labs Inc. (BIOA)vs › | $237.38M | $166.25M |
| Invivyd, Inc. (IVVD)vs › | $247.82M | $96.13M |
| MacroGenics, Inc. (MGNX)vs › | $235.50M | $156.69M |
Market Cap
$242.35M
Total Debt
$133.74M
Cash
$17.72M
Enterprise Value
$358.37M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
